Research and Clinical Trials

The OHSU Pituitary Center has established a track record as a groundbreaking research program, linking resources from across specialty areas to further insight into the cause of pituitary conditions and to develop new treatments. With several past breakthroughs and several clinical trials currently underway, we are at the forefront of investigating pituitary conditions.
Clinical trials are the last step in a lengthy process of research. These studies allow scientists to test the value of their research to diagnose, treat and prevent diseases and disabilities. Each clinical trial is an opportunity to test a promising invention or treatment.
Our research studies are focused on the medical treatment of hyperfunctioning pituitary tumors, patient outcomes, quality of life, and pituitary dysfunction before and after surgical and/or other additional therapies for pituitary adenomas.
Currently, we are involved in more than a dozen active studies for pituitary disorders that include (but are not limited to) Cushing’s disease, acromegaly and growth hormone deficiency.
As the West Coast’s most comprehensive pituitary center and one of the largest in the country, we were a major contributor to clinical studies that resulted in two new FDA-approved, first-in-their-class treatments for Cushing’s disease and one for acromegaly (e.g., glucocorticoid receptor blockers and somatostatin receptor ligands). We are involved in many international pituitary clinical trials and frequently have the highest patient participation.
Please contact us for more information.
- Trial to Compare the Efficacy and Safety of NNC0195-0092 With Placebo and Norditropin® FlexPro® in Adults With Growth Hormone Deficiency (REAL 1)
Condition: Adult Growth Hormone Deficiency
Intervention: Drug: NNC0195-0092, Drug: somatropin, Drug: placebo - Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: LCI699 - A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency
Condition: Adult Growth Hormone Deficiency
Intervention: Drug: MOD-4023 - Treatment for Endogenous Cushing's Syndrome
Condition: Endogenous Cushing's Syndrome
Intervention: Drug: COR-003
- Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
- Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (PAOLA)
- Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
- Safety and Efficacy of LCI699 in Cushing's Disease Patients
- Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study (SODA)
- An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (ACCESS)
- A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
- A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome (SEISMIC)
- An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
- Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel (SALSA)